norelgestromin (Evra) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Norelgestromin, the progestin, is the active metabolite of norgestimate and is structurally related to 19-nortestosterone. Norgestimate and norelgestromin mimic the physiologic effects of progesterone at the progesterone receptor. Johnson & Johnson developed an adhesive female contraceptive patch that contains ethinylestradiol (0.75mg) and the progestogen norelgestromin (6mg). his product is a combination contraceptive acting via the inhibition gonadotropins. Its primary mechanism of action involves the suppression of ovulation, including changes in the cervical mucus and endometrium. The patch delivers a continuous flow of hormones through the skin and into the bloodstream. The contraceptive patch is available in countries worldwide.   NCATS

Chemistry

  • SMILES: CC[C@]12CC[C@H]3[C@@H](CCC4=CC(CC[C@H]34)=NO)[C@@H]1CC[C@@]2(O)C#C
  • InChIKey: ISHXLNHNDMZNMC-VTKCIJPMSA-N
  • Mol. Mass: 327.4605
  • ALogP: 4.14
  • ChEMBL Molecule:
    norelgestromin  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Combination drugs

( ethinyl estradiol (Estinyl), norelgestromin (Evra) - other name: xulane )

Alternative names

17-deacetylnorgestimate | 17-deacylnorgestimate | 18-methylnorethindrone oxime | brn 4202099 | deacetylnorgestimate | d-norgestrel 3-oxime | evra | levonorgestrel 3-oxime | levonorgestrel oxime | levonorgestrel oxime, (3e,17alpha)-isomer | levonorgestrel oxime, (3z,17alpha)-isomer | lngo | norelgestromin | norelgestromin / ethinyl estradiol | norelgestromin-ethinyl estradiol combination patch | norplant 3-oxime | ortho evra | progestin norelgestromin | rwj-10553

Organizations (25)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Pregnancy (approved 2001)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Contraception (Phase 4)

Contraception Behavior (Early Phase 1)

Growth and Development (Phase 4)

Healthy Volunteers (Phase 4)

HIV Infections (Phase 2)

Infertility, Female (Phase 4)

Metrorrhagia (Phase 2)

Pregnancy (Phase 2)

Pregnancy Complications (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 28
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue